Royalty Report: Medical, Device, Hair loss – Collection: 110284


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Medical
  • Device
  • Hair loss
  • Supply
  • Health & Fitness
  • Cryogenic
  • cell therapy
  • Disease
  • Stem cells
  • Drugs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 110284

License Grant
Pursuant to this Sale and Exclusive License/Supply Agreement, Licensee was granted a global exclusive license to devices and consumable products for hair applications.
License Property
Celution® devices and consumable products including all future generations, comparable derivatives, successors or alternative adipose derived regenerative cell devices (hereinafter referred to as the “Celution Products”) for the “Hair Field”.

Celution 800/CRS Device An automated, electromechanical device containing multilingual, interactive software that facilitates the extraction and concentration of ADRCs, using validated algorithms programmed into the device’s software, standardizing tissue disaggregation, centrifugation and therapeutic- specific processes.

Celution 805/CRS Consumable Set A sterile, single-use set used with the Celution Device to process tissue and extract ADRCs within a closed system.

Field of Use
Licensee’s focus is on the aesthetics cash-pay market and has systems for managing male and female pattern baldness such as The Kerastem Hair Therapy, a CE mark approved for patients with alopecia (hair loss) outside the United States.

IPSCIO Record ID: 7508

License Grant
Licensor hereby grants to the Licensee an exclusive, sublicenseable, fully paid-up, license to sell and use (including but not limited to import, market, offer to sell, use, distribute, service & maintain) the Licensor Products within Fields of Use in the Territory during the Term. The right of the Licensee to grant sublicenses to any third party shall be subject to the reasonable and prompt consent of the Licensor.
License Property
The Licensed Products include

Celution 800/IV Device – An automated, electromechanical device containing multilingual, interactive software that facilitates the extraction and concentration of ADRCs, using validated algorithms programmed into the device’s software, standardizing tissue disaggregation, centrifugation and therapeutic- specific processes.

Celution 805/IV – Consumable Set A sterile, single-use set used with the Celution Device to process tissue and extract ADRCs within a closed system.

Celase Reagent – Celase® is a proprietary enzyme blend that releases ADRCs from the extracellular matrix of adipose tissue, optimized for use with the Celution device and consumable set. Celase is a sterile, pharmaceutical grade, mammalian-free reagent that is manufactured in compliance with Good Manufacturing Practices (GMP) standards.

Intravase Reagent or Reagent B – Intravase® is a sterile, GMP-grade secondary reagent used with the Celution System to prepare the Celution cell output for safe intravascular delivery. Intravase is a highly purified product to assure the lowest levels of impurities. Intravase is provided as a single-use unit which consists of a clear glass vial within a protected canister.

200/CK Convenience Kit – 200/CK Procedure Pack contains all necessary components for a single Celution procedure, including ancillary products for tissue collection, tissue processing, and delivery. The ready-to-use components are single-use, minimizing the risk of contamination for patients, healthcare staffs, surgeons, and system operators.

530/IS Tissue Collection Instrument Set – The Tissue Collection Instrument Set contains a collection of autoclavable components required for liposuction (200-360mL of tissue) under local anesthesia using a hand-held syringe.

Field of Use
Fields of Use shall mean all applications and uses of the Licensor Products in humans including but not limited to, the Cardiovascular Field, the Diabetes Field of Use, the Orthopedic Field of use. The only excluded human medical applications are the Hair Field of use, which has been previously licensed to Bimini Technologies, Inc. This definition also includes the Equine Field of Use for the treatment of horses.

IPSCIO Record ID: 4462

License Grant
Licensee is hereby granted the world-wide, perpetual, irrevocable, exclusive royalty bearing license to make, use and sell a closed system, as a part of any future Celution Product that creates an ADRC Enriched Fat Graft, provided that for each Celution Consumable sold to create an ADRC Enriched Fat Graft (that does not use a Standalone Fat Transplantation Product purchased from Licensor).
License Property
License covers any configuration of Licensor’s Standalone Fat Transplantation products, the Puregraft Products (including all future generations of each) made by or for Licensor (the “Standalone Fat Transplantation Products”), its successors and assigns to use and sell the Standalone Fat Transplantation Products for ADRC Enriched Applications (excluding only the Hair Field).

ADRC Enriched Applications includes any sale or use of the Standalone Fat Transplantation Products for the express purpose of mixing ADRC’s with Standalone Fat Transplantation Product processed fat tissue for re-implantation of the tissue into a patient.  

The Parties Agree that Licensee may not sell the Standalone Fat Transplantation Products separately, but may only offer the Standalone Fat Transplantation Products in conjunction with a Celution consumable set, whether packaged together, or bundled with one or more separately packaged products (including the consumable set).

IPSCIO Record ID: 260432

License Grant
Licensor grants to the Licensee of Japan an exclusive license to intellectual property of Licensor, for example, patents, patent applications, trade secrets, trademarks, technologies, and know-how, necessary or useful for Licensee’s use, distribution, promotion, marketing, sales, offers for sale and importation of the Devices and Products in the Field in the Territory.

The purpose of this agreement is to establish ADRC Banking facilities for the acquisition, storage and retrieval of ADRCs exclusively using Licensor’s technology, including the CelutionTM device and related products and disposables in the country of Japan.

Licensee shall purchase all CelutionTM devices, consumables,  enzymes, harvest kits and software, collectively the device, directly from Licensor.

License Property
The patent is titled Preservation of Non Embryonic Cells from Non Hematopoietic Tissues.

The Licensor Material shall include the Devices, the Packages, the Services, Licensor IP, Licensor Regulatory Information and Licensors Confidential Information.

ADRC refers to a proprietary, state-of-the-art system for adipose-derived stem and regenerative cell harvesting, processing, cryopreservation, storage, and retrieval banking that is useful in hospital settings, and Licensor has acquired and possesses certain intellectual property rights pertaining to stem and regenerative cell technology, including devices, products and services used in connection with ADRCs.

Field of Use
Celution System is a device that quickly removes regenerative cells from a patient’s own adipose tissue, and its related single-use consumables.  

The field of use is solely for the purposes of (cell) Banking in the Territory.

IPSCIO Record ID: 273421

License Grant
The Parties reached a mutual understanding that the License Agreement drafted in 2001 no longer accurately reflected the business model of the Licensee, and that it contained certain restrictions and milestones that were not optimal for the commercialization of the Invention portfolio.

With this amendment, The University Regents grant a world-wide license under The Universitys undivided interest in Patent Rights to make, have made, use, sell, offer to sell and import Product and to practice Licensed Method in the Field.

License Property
This license is for certain inventions, generally characterized as Adipose-Derived Stem Cells and Lattices.

The patents include Isolation of Stromal Cells from Adipose Tissue, Isolation of Mesenchymal Stem Cells from Adipose Tissue, and, Adipose-Derived Stem Cells and Lattices.

Product means Research Product and Clinical Product.

Field of Use
The Field means any and all products and/or services for the research, diagnosis, and/or therapy of disease and/or disorders in humans and for cosmetic applications in humans.

Licensee is commercializing an automated device called Celution, which when operated in conjunction with various disposable component parts is capable of producing a heterogeneous isolate of the material naturally occurring in adipose tissue including unmodified amounts of stem cells and other regenerative cells, intended for human therapeutic, diagnostic, cosmetic and other uses.

The patented Celution® family of products process patients’ adipose-derived stem and regenerative cells (ADRCs) at the point of care. The Celution® family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation.  Licensee commercialization model is based on the sale of Celution® Systems and on generating recurring revenues from the single-use consumable sets.

Commercial activities are currently focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, where Cytori’s core product, the Celution® System, provides physicians with clinical grade stem and regenerative cells.

IPSCIO Record ID: 383570

License Grant
The University grants to Licensee of Bermuda an exclusive, worldwide right and license, with the right to sublicense, under University Patent Rights to make, have made, use, sell, offer for sale and import Product in the Field of Use during the Term.
License Property
The University owns and controls certain innovative technology for regrowth of hair.

The patents are
— Prostaglandin D2 Synthase and its Products as Cause of Hair Loss and Target for Therapy;
— Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia.

Field of Use
The Field of Use means hair growth and hair removal in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.